Conceptual Model for HIV Post-Trial Care | Abstract
Journal of Clinical Trials

Journal of Clinical Trials
Open Access

ISSN: 2167-0870

+44 20 3868 9735


Conceptual Model for HIV Post-Trial Care

Jan Fasisco*

Antiretroviral Treatment (ART) reduces the danger of developing
active tuberculosis (TB) in HIV-1 co-infected persons. So as to
know host immune responses during ART within the context
of tubercle bacillus (Mtb) sensitization, we performed RNAseq
analysis of whole blood-derived RNA from HIV-1 infected patients
during the primary 6 months of ART. A big fall in RNA sequence
abundance of the Hallmark IFN-alpha, IFN-gamma, IL- 6/JAK/
STAT3 signaling, and inflammatory response pathway genes
indicated reduced immune activation and inflammation at 6
months of ART compared to day 0. Further exploratory evaluation of 65 soluble analytes in plasma confirmed the many decrease of
inflammatory markers after 6 months of ART. Next, we evaluated 30 soluble analytes in QuantiFERON Gold in-tube (QFT) samples
from the Ag stimulated and Nil tubes, during the primary 6 months
of ART in 30 patients.

Published Date: 2020-12-25; Received Date: 2020-12-04